Fibrocell Science Inc (FCSC)

[DewDiligence]

#4 is…just your opinion.

It’s actually more than that. In the past decade or so, whenever I’ve heard the CEO of a small biotech company proclaim that the company is “in active discussions with the FDA,” it always turned out to be a harbinger of bad news. The reason is obvious when you think about it: if discussions with the FDA were genuinely progressing in a meaningful way, it would be possible to give specifics on the timing of meetings, submissions, approved protocols, or other concrete milestones.

I’ll make a gentlemen’s bet with you (or anyone else on this board) that a phase-3 Laviv trial for acne scars will not start during the next year and will not finish during the next three years.